BioNTech to Host AI Day on October 1, 2025, in London.
ByAinvest
Tuesday, Sep 23, 2025 6:49 am ET1min read
BNTX--
The event will take place at 9:00 AM EDT (3:00 PM CEST) and will be accessible via a live webcast. Participants can also access the slides and a recording of the event through BioNTech's website, where the recording will be archived for one year following the event. [1]
BioNTech's AI strategy aims to leverage advanced computational techniques to accelerate the development of novel biopharmaceuticals. The company's portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, targeted therapies such as antibody-drug conjugates (ADCs), and innovative chimeric antigen receptor (CAR) T cell therapies. [1]
By showcasing its AI capabilities and applications, BioNTech aims to provide investors and stakeholders with a comprehensive understanding of its innovative approach to drug development. The event is expected to offer valuable insights into the company's strategic direction and the potential impact of AI on the biopharmaceutical industry. [1]
BioNTech SE, a biopharmaceutical company, will host its second AI Day on October 1, 2025, in London. The event will showcase BioNTech's AI strategy and capabilities, as well as its applications in the company's pipeline and internal processes. The live webcast will be available via a link on BioNTech's website, and a recording will be archived for one year.
BioNTech SE, a leading biopharmaceutical company, will host its second AI Day on October 1, 2025, in London. The event, part of BioNTech's "Innovation Series," will focus on the company's artificial intelligence strategy and capabilities, highlighting the applications of AI in its pipeline and internal processes. This event marks a significant milestone in BioNTech's continued focus on AI development, following its acquisition of InstaDeep Ltd. [1]The event will take place at 9:00 AM EDT (3:00 PM CEST) and will be accessible via a live webcast. Participants can also access the slides and a recording of the event through BioNTech's website, where the recording will be archived for one year following the event. [1]
BioNTech's AI strategy aims to leverage advanced computational techniques to accelerate the development of novel biopharmaceuticals. The company's portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, targeted therapies such as antibody-drug conjugates (ADCs), and innovative chimeric antigen receptor (CAR) T cell therapies. [1]
By showcasing its AI capabilities and applications, BioNTech aims to provide investors and stakeholders with a comprehensive understanding of its innovative approach to drug development. The event is expected to offer valuable insights into the company's strategic direction and the potential impact of AI on the biopharmaceutical industry. [1]
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet